跳至主要内容
临床试验/NCT06697106
NCT06697106招募中不适用

Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?

New Valley University1 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2024年11月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
82
试验地点
1
主要终点
Urethral stricture recurrence

研究概览

简要总结

To evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing urethral stricture recurrence after direct visual internal urethrotomy.

详细描述

The most common aetiology of urethral strictures is idiopathic, followed by iatrogenic causes, including transurethral resection, urethral catheterization, prostate cancer treatments, and previous hypospadias surgery.

The recurrence rates are higher with previously treated, long and multiple strictures, penile compared with bulbar strictures, and those with perioperative infection.

It has been reported that post-transurethral resection of the prostate (TURP) to receive or not receive a COX-2 inhibitor (rofecoxib 25 mg/day) for 20 days. At 1 year of follow-up, a urethral stricture had been diagnosed in 17 and 0 % of cases without and with COX-2 treatment, respectively

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • American Society of Anesthesiologists (ASA) score ≤
  • Urethral stricture length ≤ 1.5 cm

排除标准

  • Recurrent urethral stricture ≥ 2 times.
  • Pelvic fracture urethral distraction defect (PFUDD).

研究组 & 干预措施

Nonsteroidal anti-inflammatory drugs

Experimental

Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.

干预措施: Nonsteroidal anti-inflammatory drugs (Drug)

Control group

Placebo Comparator

Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.

干预措施: Placebo (Drug)

结局指标

主要结局

Urethral stricture recurrence

时间窗: 90 days postoperative

Urethral stricture recurrence is defined as the need for a secondary procedure, including dilation, internal urethrotomy, and urethroplasty, considered as treatment failure.

次要结局

  • International Prostate Symptom Score (IPSS)(90 days postoperative)
  • Quality of life (QOL)(90 days postoperative)
  • Maximum flow rate(90 days postoperative)
  • Incidence of complications(90 days postoperative)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Waheed Fawzy Abdelrasol

Lecturer of Urology, Faculty of medicine, New Vally University, New Vally, Egypt

New Valley University

研究点 (1)

Loading locations...

相似试验